Ultra‐Specific Isolation of Circulating Tumor Cells Enables Rare‐Cell RNA Profiling

Abstract

<b>The clinical potential of circulating tumor cells (CTCs)</b> in managing cancer metastasis is significant. However, low CTC isolation purities from patient blood have hindered sensitive molecular assays of these rare cells. Described herein is the ultra-pure isolation of CTCs from patient blood samples and how this platform has enabled highly specific molecular (mRNA and miRNA) profiling of patient CTCs.